BRPI0818193A2 - compound, pharmaceutically acceptable salt of a compound, pharmaceutical composition, and use of a compound - Google Patents
compound, pharmaceutically acceptable salt of a compound, pharmaceutical composition, and use of a compoundInfo
- Publication number
- BRPI0818193A2 BRPI0818193A2 BRPI0818193A BRPI0818193A BRPI0818193A2 BR PI0818193 A2 BRPI0818193 A2 BR PI0818193A2 BR PI0818193 A BRPI0818193 A BR PI0818193A BR PI0818193 A BRPI0818193 A BR PI0818193A BR PI0818193 A2 BRPI0818193 A2 BR PI0818193A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salt
- pharmaceutical
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/613—Unsaturated compounds containing a keto groups being part of a ring polycyclic
- C07C49/617—Unsaturated compounds containing a keto groups being part of a ring polycyclic a keto group being part of a condensed ring system
- C07C49/623—Unsaturated compounds containing a keto groups being part of a ring polycyclic a keto group being part of a condensed ring system having two rings
- C07C49/627—Unsaturated compounds containing a keto groups being part of a ring polycyclic a keto group being part of a condensed ring system having two rings the condensed ring system containing seven carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/32—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/20—All rings being cycloaliphatic the ring system containing seven carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/93—Spiro compounds
- C07C2603/94—Spiro compounds containing "free" spiro atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR122013020635-3A BR122013020635A2 (en) | 2007-09-28 | 2008-09-25 | COMPOUND |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007-255430 | 2007-09-28 | ||
| JP2007255430 | 2007-09-28 | ||
| PCT/JP2008/067223 WO2009041453A1 (en) | 2007-09-28 | 2008-09-25 | Bicyclic γ-amino acid derivative |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0818193A2 true BRPI0818193A2 (en) | 2017-12-12 |
| BRPI0818193B1 BRPI0818193B1 (en) | 2020-11-10 |
| BRPI0818193B8 BRPI0818193B8 (en) | 2021-05-25 |
Family
ID=40511336
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0818193A BRPI0818193B8 (en) | 2007-09-28 | 2008-09-25 | compound, pharmaceutical composition, and use of a compound |
| BR122013020635-3A BR122013020635A2 (en) | 2007-09-28 | 2008-09-25 | COMPOUND |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR122013020635-3A BR122013020635A2 (en) | 2007-09-28 | 2008-09-25 | COMPOUND |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7947738B2 (en) |
| EP (2) | EP2192109B1 (en) |
| JP (1) | JP4479974B2 (en) |
| KR (2) | KR101409079B1 (en) |
| CN (2) | CN103483169A (en) |
| AU (1) | AU2008304933B2 (en) |
| BR (2) | BRPI0818193B8 (en) |
| CA (1) | CA2701110C (en) |
| CO (1) | CO6270314A2 (en) |
| CY (1) | CY1114836T1 (en) |
| DK (1) | DK2192109T3 (en) |
| ES (2) | ES2531324T3 (en) |
| HR (1) | HRP20130935T1 (en) |
| IL (1) | IL204621A (en) |
| MX (1) | MX2010003394A (en) |
| MY (2) | MY153910A (en) |
| NZ (1) | NZ584699A (en) |
| PH (1) | PH12013501663B1 (en) |
| PL (1) | PL2192109T3 (en) |
| PT (1) | PT2192109E (en) |
| RU (1) | RU2446148C2 (en) |
| SI (1) | SI2192109T1 (en) |
| TW (2) | TWI436762B (en) |
| WO (1) | WO2009041453A1 (en) |
| ZA (1) | ZA201002013B (en) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2531324T3 (en) | 2007-09-28 | 2015-03-13 | Daiichi Sankyo Co Ltd | Intermediate to produce a bicyclic gamma-amino acid derivative |
| WO2010079668A1 (en) * | 2009-01-08 | 2010-07-15 | 第一三共株式会社 | Olefin compound |
| WO2010110361A1 (en) | 2009-03-26 | 2010-09-30 | 第一三共株式会社 | Method for producing bicyclic γ-amino acid derivative |
| ES2649968T3 (en) * | 2011-06-08 | 2018-01-16 | Daiichi Sankyo Company, Limited | Production procedure of a bicyclic compound via Claisen transposition |
| BR112013031360B1 (en) * | 2011-06-08 | 2022-01-25 | Daiichi Sankyo Company, Limited | Method to make a compound |
| CA2859003C (en) * | 2011-12-15 | 2016-11-01 | Daiichi Sankyo Company, Limited | Optical resolution method for bicyclic compound using asymmetric catalyst |
| WO2013089189A1 (en) * | 2011-12-16 | 2013-06-20 | 第一三共株式会社 | Optical resolution method for bicyclic compound using hydroxysulfonic acid |
| EP2813513B1 (en) * | 2012-02-08 | 2019-07-03 | Stella Pharma Corporation | Method for producing cereulide and derivative thereof, intermediate for production of cereulide, and cereulide derivative |
| KR101976891B1 (en) * | 2012-04-10 | 2019-05-09 | 다이이찌 산쿄 가부시키가이샤 | Optical resolution method for bicyclic compound using enzyme |
| IN2014MN02116A (en) | 2013-04-04 | 2015-09-04 | Daiichi Sankyo Companyltd | |
| TWI635071B (en) * | 2013-07-08 | 2018-09-11 | 第一三共股份有限公司 | OPTICALLY ACTIVE BICYCLIC γ-AMINO ACID AND PREPARATION METHOD FOR THE SAME |
| JP6491213B2 (en) * | 2013-12-18 | 2019-03-27 | ノヴァッセイ エスエー | Gamma-aminobutyric acid (GABA) analogs for the treatment of pain and other disorders |
| BR112017019920B1 (en) | 2015-03-19 | 2023-11-07 | Daiichi Sankyo Company, Limited | SOLID PHARMACEUTICAL PREPARATION, AND METHOD FOR STABILIZING A SOLID PHARMACEUTICAL PREPARATION |
| US10561628B2 (en) | 2015-03-19 | 2020-02-18 | Daiichi Sankyo Company, Limited | Solid preparation including antioxidant |
| CN107848953B (en) * | 2015-12-25 | 2021-05-18 | 四川海思科制药有限公司 | Condensed ring γ-amino acid derivative, preparation method and medical application thereof |
| WO2017114225A1 (en) * | 2015-12-31 | 2017-07-06 | 四川海思科制药有限公司 | Fused tricyclic γ-amino acid derivative and preparation method and pharmaceutical application thereof |
| CN106928080B (en) * | 2015-12-31 | 2020-12-25 | 四川海思科制药有限公司 | Fused ring gamma-amino acid derivative, preparation method and application thereof in medicine |
| WO2017183539A1 (en) * | 2016-04-18 | 2017-10-26 | 第一三共株式会社 | Method for producing bicyclic compound using meldrum's acid |
| TW201806928A (en) * | 2016-07-01 | 2018-03-01 | 第一三共股份有限公司 | Crystals of aminocarboxylic acid acid addition salts and the synthetic method thereof |
| ES2906887T3 (en) * | 2016-07-21 | 2022-04-20 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Indole derivative used as a CRTH2 inhibitor |
| MY196788A (en) * | 2016-09-14 | 2023-05-03 | Sichuan Haisco Pharmaceutical Co Ltd | Fused tricyclic ?-amino acid derivative, preparation method therefor, and medical use thereof |
| JP7051332B2 (en) * | 2017-08-23 | 2022-04-11 | キヤノン株式会社 | Organic compounds and photoelectric conversion elements |
| TW202019871A (en) * | 2018-07-12 | 2020-06-01 | 大陸商四川海思科製藥有限公司 | Crystal form of salt of fused tricyclic [gamma]-amino acid derivative and preparation and use thereof |
| MX2021000403A (en) | 2018-07-12 | 2021-03-25 | Sichuan Haisco Pharmaceutical Co Ltd | COMPOSITION OF FUSIONED GAMMA TRICYCLIC AMINO ACID DERIVATIVES AND THE PREPARATION THEREOF. |
| BR112021001008A2 (en) * | 2018-07-30 | 2021-04-20 | Daiichi Sankyo Company, Limited | drug tablet |
| CN112384493B (en) * | 2018-08-09 | 2023-06-06 | 四川海思科制药有限公司 | Preparation method and intermediate of fused tricyclic γ-amino acid derivatives |
| WO2021043117A1 (en) * | 2019-09-03 | 2021-03-11 | 四川海思科制药有限公司 | Impurity detection method for 2-((1s,2s,3r,6s,8s)-2-(aminomethyl)tricyclo[4.2.1.0 3,8]nonane-2-yl)acetate benzenesulfonate or composition thereof |
| CN110511141B (en) * | 2019-09-09 | 2022-04-29 | 上海凌凯医药科技有限公司 | Synthesis method of valproyl urea |
| US20220296548A1 (en) | 2019-10-25 | 2022-09-22 | Kyoto University | Preventative or therapeutic agent for tauopathy |
| CN110818582B (en) * | 2019-11-20 | 2023-06-09 | 合肥拓锐生物科技有限公司 | GABA analogue and salt thereof, and synthetic method, application and medicine thereof |
| CN111116345A (en) * | 2019-12-30 | 2020-05-08 | 上海华理生物医药股份有限公司 | Novel method for preparing Mirogabalin |
| CA3216507A1 (en) | 2021-05-12 | 2022-11-17 | Boehringer Ingelheim International Gmbh | Pyridine derivatives with c-linked cyclic substituents as cgas inhibitors |
| CN114195661B (en) * | 2021-12-21 | 2023-12-22 | 苏州楚凯药业有限公司 | Preparation method of milobalin benzenesulfonate |
| CN117986143A (en) * | 2022-11-03 | 2024-05-07 | 中科中山药物创新研究院 | Gamma-aminobutyric acid derivatives containing polycyclic structures and preparation methods and uses thereof |
| CN116903468B (en) * | 2023-07-14 | 2024-01-26 | 山东新时代药业有限公司 | Preparation method of milbelin intermediate |
| CN117623957A (en) * | 2023-12-04 | 2024-03-01 | 中国药科大学 | A diastereoisomer of milopaline besylate [(1R,5S,6R)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-ene-6- Synthetic method of benzenesulfonate acetate |
| CN117800858B (en) * | 2023-12-28 | 2024-06-21 | 南京津泓科技有限公司 | Preparation method for catalytic cyanation of milbelin |
| TW202535348A (en) * | 2024-01-08 | 2025-09-16 | 大陸商海思科醫藥集團股份有限公司 | Use of a fused tricyclic γ-amino acid derivative in treating central nervous system pathological pain |
| CN118420477B (en) * | 2024-07-01 | 2024-10-29 | 中节能万润股份有限公司 | Preparation method of milobalin benzenesulfonate |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19547766A1 (en) * | 1995-12-20 | 1997-06-26 | Gruenenthal Gmbh | 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as active pharmaceutical ingredients |
| US6635673B1 (en) | 1997-10-27 | 2003-10-21 | Warner-Lambert Company | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents |
| HN2000000224A (en) | 1999-10-20 | 2001-04-11 | Warner Lambert Co | BICYCLE AMINO ACIDS AS PHARMACEUTICAL AGENTS |
| GB2374595A (en) * | 2001-04-19 | 2002-10-23 | Warner Lambert Co | Fused bicyclic or tricyclic amino acids |
| DE60235619D1 (en) * | 2001-04-19 | 2010-04-22 | Warner Lambert Co | CONCENTRATED BICYCLIC OR TRICYCLIC AMINO ACIDS |
| JP2005536507A (en) | 2002-07-11 | 2005-12-02 | メルク エンド カムパニー インコーポレーテッド | Treatment of neuropathic pain with 6H-pyrrolo [3,4-d] pyridazine compounds |
| GB0223072D0 (en) * | 2002-10-04 | 2002-11-13 | Pfizer Ltd | Cyclic nitromethyl acetic acid derivatives |
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| ES2531324T3 (en) | 2007-09-28 | 2015-03-13 | Daiichi Sankyo Co Ltd | Intermediate to produce a bicyclic gamma-amino acid derivative |
-
2008
- 2008-09-25 ES ES13177681T patent/ES2531324T3/en active Active
- 2008-09-25 CA CA2701110A patent/CA2701110C/en active Active
- 2008-09-25 JP JP2009534336A patent/JP4479974B2/en active Active
- 2008-09-25 RU RU2010116708/04A patent/RU2446148C2/en active
- 2008-09-25 BR BRPI0818193A patent/BRPI0818193B8/en active IP Right Grant
- 2008-09-25 WO PCT/JP2008/067223 patent/WO2009041453A1/en not_active Ceased
- 2008-09-25 KR KR1020137020763A patent/KR101409079B1/en active Active
- 2008-09-25 CN CN201310389454.8A patent/CN103483169A/en active Pending
- 2008-09-25 NZ NZ584699A patent/NZ584699A/en unknown
- 2008-09-25 EP EP08833399.2A patent/EP2192109B1/en active Active
- 2008-09-25 MY MYPI2010001048A patent/MY153910A/en unknown
- 2008-09-25 AU AU2008304933A patent/AU2008304933B2/en active Active
- 2008-09-25 KR KR1020107006640A patent/KR101335784B1/en active Active
- 2008-09-25 HR HRP20130935AT patent/HRP20130935T1/en unknown
- 2008-09-25 BR BR122013020635-3A patent/BR122013020635A2/en not_active Application Discontinuation
- 2008-09-25 MY MYPI2013003126A patent/MY172034A/en unknown
- 2008-09-25 EP EP13177681.7A patent/EP2657219B1/en active Active
- 2008-09-25 DK DK08833399.2T patent/DK2192109T3/en active
- 2008-09-25 SI SI200831100T patent/SI2192109T1/en unknown
- 2008-09-25 ES ES08833399T patent/ES2433890T3/en active Active
- 2008-09-25 PL PL08833399T patent/PL2192109T3/en unknown
- 2008-09-25 PT PT88333992T patent/PT2192109E/en unknown
- 2008-09-25 CN CN200880118892.8A patent/CN101878193B/en active Active
- 2008-09-25 MX MX2010003394A patent/MX2010003394A/en active IP Right Grant
- 2008-09-26 TW TW097137036A patent/TWI436762B/en active
- 2008-09-26 TW TW103112429A patent/TWI526425B/en active
-
2010
- 2010-02-26 US US12/714,267 patent/US7947738B2/en active Active
- 2010-03-19 ZA ZA2010/02013A patent/ZA201002013B/en unknown
- 2010-03-21 IL IL204621A patent/IL204621A/en active IP Right Grant
- 2010-04-28 CO CO10050291A patent/CO6270314A2/en active IP Right Grant
-
2013
- 2013-08-08 PH PH12013501663A patent/PH12013501663B1/en unknown
- 2013-12-03 CY CY20131101078T patent/CY1114836T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0818193A2 (en) | compound, pharmaceutically acceptable salt of a compound, pharmaceutical composition, and use of a compound | |
| BRPI0917540A2 (en) | compound, pharmaceutically acceptable salt, pharmaceutical composition, and use of a pharmacologically acceptable compound or salt | |
| BRPI0810696A2 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND | |
| BRPI0810161A2 (en) | COMPOUND, PHARMACEUTICAL PREPARATION, PHARMACEUTICAL COMPOSITION, AND USE OF A COMPOUND | |
| BRPI1013988A2 (en) | compound, pharmaceutical composition, and use of a compound or a pharmaceutically acceptable salt thereof | |
| BRPI0919942A2 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND | |
| BRPI0907562A2 (en) | compound, pharmaceutical composition, and use of a compound | |
| BRPI0921375A2 (en) | compound, pharmaceutical composition, and use of a compound | |
| BRPI0821115A2 (en) | Aminotriazole-derived compound, drug, pharmaceutical composition and use of compound | |
| BRPI0815709A2 (en) | composition, pharmaceutical composition, and use of a compound. | |
| BRPI0607545A2 (en) | compound, use of a compound of formula I or a pharmaceutically acceptable salt thereof, and pharmaceutical composition | |
| BRPI0819696A2 (en) | Compounds of 2-phenylpyrimidine derivatives, pharmaceutical composition and use of a compound | |
| BRPI0716171A2 (en) | compound, pharmaceutical composition and use of a compound. | |
| BRPI0917579A2 (en) | compound, pharmaceutical composition, methods, and use of a compound | |
| BRPI1016219A2 (en) | compound, pharmaceutical composition, and use of a compound | |
| BRPI1008793A2 (en) | compound use of a compound and pharmaceutical composition | |
| BRPI0609802A2 (en) | compound, pharmaceutical composition and use of a compound | |
| BRPI0921879A2 (en) | compound, pharmaceutical composition, and use of a compound | |
| BRPI0516609A (en) | pharmaceutically acceptable compound or salt, hydrate, or stereoisomer thereof, pharmaceutical composition, and use of a compound | |
| BRPI0812942A2 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION AND USE OF A COMPOUND | |
| BRPI0810019A2 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND | |
| BRPI0822033A2 (en) | Compound or salt thereof, pharmaceutical composition, use of a compound or salt, and kit | |
| BRPI1007018A2 (en) | compound, pharmaceutical composition, and use of a compound. | |
| BRPI0716698A2 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION AND USE OF A COMPOUND | |
| BRPI1008906A2 (en) | compound, pharmaceutical composition, and use of a compound. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/09/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |